Whitehawk Therapeutics announced two real-world analyses supporting PTK7 as a durable and clinically relevant ADC target in pretreated, EGFR wild-type non-small cell lung cancer, presented at the IASLC 2026 World Conference on Lung Cancer in Seoul. In tumor samples from patients with EGFR wild-type lung adenocarcinoma, PTK7 expression remained largely stable following standard-of-care chemotherapy and immunotherapy and showed less treatment-associated variation than several late-stage ADC targets including MET, PD-L1 and ITGB6, with expression generally consistent across tumors with or without other actionable genomic alterations such as KRAS G12C, ALK and MET. A separate analysis found real-world overall survival was not impacted by PTK7 expression, supporting PTK7 as a target-engagement biomarker independent of prognosis. The findings reinforce the scientific rationale for HWK-007, Whitehawk's next-generation PTK7-directed ADC in Phase 1 development for non-squamous EGFR wild-type NSCLC, platinum-resistant ovarian cancer and endometrial cancer. The analyses were conducted under a previously announced collaboration between Whitehawk and Tempus AI.
Whitehawk Therapeutics, Inc.Real-world data reinforce PTK7 as a durable ADC target and the scientific rationale for Whitehawk's Phase 1 HWK-007.
Tempus AI, Inc. Class A Common StockWhitehawk's PTK7 analyses were conducted under its collaboration with Tempus AI, supporting Tempus's data/AI platform role in the research.
